At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KZR Kezar Life Sciences Inc.
Pre-Market Trading 11-15 06:41:05 EST
7.52
-0.02
-0.27%
High7.59
Low7.41
Vol14.83K
Open7.54
D1 Closing7.54
Amplitude2.39%
Mkt Cap54.87M
Tradable Cap34.17M
Total Shares7.30M
T/O111.76K
T/O Rate0.33%
Tradable Shares4.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Kezar Life Sciences Inc: on November 13, Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.